DPP4 and heart failure: One newer class of oral antihyperglycemic agents, dipeptidyl peptidase-IV inhibitors (DPP-4i), has elicited increased reports of hospitalization for heart failure to the United States Food and Drug Administration Adverse Event Reporting System [6, 7].